evipedia.ai
← Back

NAD+ for Health & Longevity

Evidence Review created on 10/15/2026 using AI4L / Opus 5.5

Also known as: Nicotinamide Adenine Dinucleotide, NAD, β-NAD, Nadide, Coenzyme I, Cozymase, Diphosphopyridine Nucleotide, DPN

Motivation

NAD+ (nicotinamide adenine dinucleotide) is a small molecule found in every living cell. It helps turn food into usable energy and is used up by enzymes that repair genetic material and help cells cope with stress. Because some researchers propose that levels fall with age, raising NAD+ has become one of the most widely discussed ideas in the longevity field.

Interest follows two routes. One is delivering NAD+ itself, most often as slow intravenous infusions at wellness clinics, but also as capsules, nasal sprays and skin patches. The other is taking close relatives of vitamin B3 that the body converts into NAD+. Research has looked at energy and fatigue, heart and metabolic health, and brain aging, and infusion clinics now offer the treatment in many cities.

This review examines the human evidence for NAD+ itself and, where direct data are missing, for the vitamin B3 building blocks the body turns into it. It weighs reported benefits against infusion reactions, product quality concerns and long-term unknowns, to set out what is and is not known about NAD+ for health and longevity.

Benefits - Risks - Protocol - Conclusion

This section lists expert articles and podcasts that give a high-level overview of NAD+ and NAD+-boosting strategies.

Content from Chris Kresser was not listed: his 2020 interview with David Sinclair discusses NAD+ and NMN within a broad aging conversation, but all five slots went to priority platforms with NAD+-focused content.

Grokipedia

NAD+ supplements

A broad overview of NAD+ supplementation covering precursors, injectable and oral forms, bioavailability problems, claimed benefits, dosing and regulation; useful orientation, though weighted toward animal findings.

Examine

Nicotinamide Adenine Dinucleotide

Summarizes NAD+ as a metabolic cofactor, why levels fall with age and whether NADH (the reduced form of NAD+) raises NAD+; detailed evidence grading requires a paid membership.

ConsumerLab

NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, and NMN)

Independent lab tests of NAD+, NADH, NR and NMN products for label accuracy and contamination, with cost comparisons and a warning that some products exceed vitamin B3 upper limits.

Systematic Reviews

These systematic reviews and meta-analyses (statistical pooling of several studies) cover NAD+ itself, its reduced form, and the precursors used to raise it.

No systematic review or meta-analysis has assessed the safety of intravenous NAD+ specifically; the two safety-focused reviews cover oral NADH and NMN.

Mechanism of Action

NAD+ shuttles electrons in the reactions that turn food into ATP (the cell’s energy currency). It is also used up as a fuel by three enzyme families: sirtuins (gene-regulating enzymes tied to stress resistance), PARPs (poly(ADP-ribose) polymerases, DNA-repair enzymes) and CD38 (an immune-cell enzyme that breaks NAD+ down). Because inflammation drives CD38-rich immune cells to accumulate in tissues, NAD+ falls in aged mice, and the rationale for supplementation is to restore sirtuin and repair activity (Covarrubias et al., 2020).

The competing view holds that whole-blood NAD+ does not decline with age in humans (Trętowicz et al., 2026) and that extra NAD+ can also feed inflammatory signaling from senescent (damaged, non-dividing) cells (Nacarelli et al., 2019).

Key pharmacological properties:

  • Half-life: none established. During a 6-hour IV infusion of 750 mg, plasma NAD+ did not rise for 2 hours, then rose about 400% above baseline by 6 hours (Grant et al., 2019; several authors work for an IV NAD+ clinic and its research arm).
  • Selectivity and distribution: NAD+ is charged and crosses membranes poorly; it acts on all tissues, largely after breakdown to nicotinamide (NAM), NMN and NR, and orally administered NAD+ is mostly degraded in the gut.
  • Metabolism: CD38 and pyrophosphatases (enzymes that split NAD+) clear it; NNMT (nicotinamide N-methyltransferase, a liver enzyme that tags nicotinamide for removal) prepares it for urinary excretion. No CYP (cytochrome P450 liver drug-metabolizing) enzyme is involved.

Historical Context & Evolution

NAD+ was first identified in the early twentieth century as a coenzyme in yeast fermentation. Its importance for people became clear when pellagra (a deadly disease of diarrhea, skin inflammation and dementia) was found to be curable with foods containing niacin, an NAD+ building block (Grant et al., 2019). Its original medical use was therefore nutritional: preventing vitamin B3 deficiency.

Direct NAD+ therapy followed. Grant and colleagues cite a 1961 report that IV NAD+ eased alcohol withdrawal (Grant et al., 2019), a practice later continued by addiction clinics, though the supporting reports remained uncontrolled case series (Blum et al., 2024).

Interest for longevity came in the 2000s, when NAD+-dependent sirtuins were linked to the benefits of calorie restriction and NAD+ was found to fall in aged tissues. In 2016, mouse studies reported that NR and NMN improved stem-cell function, metabolism and lifespan (Zhang et al., 2016; Mills et al., 2016). These findings launched a supplement market and, later, IV NAD+ in wellness clinics.

Opinion has since moved toward caution because of new evidence: NR did not extend lifespan in the National Institute on Aging’s Interventions Testing Program (Harrison et al., 2021), human precursor trials raised NAD+ but often without clinical gains (Gallagher & Emmanuel, 2026), and a large Parkinson’s disease trial favored placebo (Brakedal et al., 2026). Supporters point to a positive heart-failure trial of IV NAD+ (Yu et al., 2026) and to fatigue studies, so the question remains open.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no clinical outcome of NAD+ itself has been shown in controlled trials from more than one independent research group.

Medium 🟩 🟩

Heart pumping function in ischemic heart failure

In a single-center Chinese placebo-controlled randomized trial by Yu et al., 180 adults with heart failure from ischemic cardiomyopathy (heart muscle damaged by poor blood supply) received 10 mg/day IV NAD+ or placebo for 7 days alongside standard drugs. Left ventricular ejection fraction (LVEF, the share of blood the main pumping chamber ejects per beat) rose more with NAD+ over 1 month. Fewer heart-failure hospitalizations were only a trend. The proposed mechanism is restored heart-muscle energy supply; no independent group has replicated the finding.

Magnitude: LVEF rose 4.49 percentage points with NAD+ versus 2.25 with placebo over 1 month (p = 0.023, a p-value, the chance of a gap this large if NAD+ had no effect; no between-group difference or confidence interval reported); major cardiac or cerebrovascular events at 6 months were 14.6% versus 24.7%, not statistically significant (Yu et al., 2026).

Low 🟩

Blood pressure ⚠️ Conflicted

Evidence is indirect: trials used NR or NMN, not NAD+. A crossover trial (each person received both treatments) by Martens hinted at lower systolic pressure; a meta-analysis of 10 NMN trials (Zhang) found only a small diastolic drop. Net reading: at most a small effect, mainly after age 60.

Magnitude: NMN versus placebo lowered diastolic pressure by 2.15 mmHg (95% CI, confidence interval, the range likely to contain the true effect: −3.68 to −0.61); systolic change was not significant overall but was 3.94 mmHg lower (95% CI −7.06 to −0.82) in adults aged 60 or older (Zhang et al., 2026; see also Martens et al., 2018).

Insulin sensitivity and blood sugar control ⚠️ Conflicted

Evidence is indirect (precursors, not NAD+). NMN raised muscle insulin sensitivity in prediabetic women (Yoshino et al., 2021), but NR at 2,000 mg/day did not in obese men (Dollerup et al., 2018), and pooled NMN trials showed no glucose benefit. Net reading: no consistent improvement in blood sugar control.

Magnitude: HOMA-IR (an insulin-resistance score) fell 0.27 units more with NMN than placebo (95% CI −0.01 to 0.55), not statistically significant; fasting glucose, fasting insulin and HbA1c (3-month average blood sugar) did not change (Chen et al., 2024).

Muscle strength and physical function ⚠️ Conflicted

Evidence is indirect (NMN, NR). Pooled NMN trials in older adults did not change muscle mass, grip or gait; another meta-analysis found NMN improved endurance, not strength. NR improved walking in peripheral artery disease (narrowed leg arteries) (McDermott et al., 2024). Net reading: possible endurance gain, no muscle benefit.

Magnitude: NMN versus placebo: gait speed −0.01 m/s (95% CI −0.08 to 0.06) and handgrip strength +0.61 kg (95% CI −0.89 to 2.10), neither significant (Prokopidis et al., 2025); high-dose NMN improved endurance, standardized mean difference (SMD, effect size in standard-deviation units) 1.02 (95% CI 0.43 to 1.60) (Gao et al., 2026).

Fatigue ⚠️ Conflicted

Evidence is indirect: NADH plus coenzyme Q10 (a mitochondrial nutrient) lowered fatigue in chronic fatigue syndrome (Castro-Marrero et al., 2015); NAD+ patches with low-dose naltrexone helped long-COVID fatigue in an uncontrolled, company-run study. NR and pooled precursor trials showed no benefit (Gao et al., 2026). Net reading: no consistent benefit.

Magnitude: The Chalder fatigue score fell from 25.9 to 17.4 over 12 weeks with NAD+ patches plus low-dose naltrexone (no control group) (Isman et al., 2024); NR versus placebo showed no difference in fatigue severity (Wu et al., 2025).

Cognitive function ⚠️ Conflicted

Evidence is indirect (NADH, NR). A 26-patient Alzheimer’s trial of oral NADH reported better dementia-rating scores (Demarin et al., 2004), but NR failed to improve cognition in mild cognitive impairment (Orr et al., 2024; Martens et al., 2026) and long COVID. Net reading: no benefit in the stronger trials.

Magnitude: Pooled NADH trials improved cognitive performance versus control, SMD 1.50 (95% CI 0.82 to 2.19), a result sensitive to influential studies (Gao et al., 2026); NR showed no between-group difference on any cognitive test versus placebo (Wu et al., 2025).

Parkinson’s disease symptoms ⚠️ Conflicted

Evidence is indirect (NR). A 30-patient pilot linked rising brain NAD+ to mild clinical improvement (Brakedal et al., 2022), but the 410-patient NOPARK trial found NR worsened symptom scores over 52 weeks. Net reading: no benefit, with a harm signal.

Magnitude: Total MDS-UPDRS (the standard Parkinson’s severity scale) rose 2.72 points more with NR than placebo (95% CI 0.47 to 4.98) (Brakedal et al., 2026).

Skin cancer prevention ⚠️ Conflicted

Evidence is indirect: trials used nicotinamide, the vitamin B3 form NAD+ is built from. In people with prior skin cancers, nicotinamide reduced new non-melanoma skin cancers, but it had no effect in organ-transplant recipients. Net reading: benefit limited to high-risk people with normal immunity.

Magnitude: New non-melanoma skin cancers were 23% lower than placebo at 12 months (95% CI 4 to 38), a mean of 1.8 versus 2.4 per person (336 versus 463 cancers) (Chen et al., 2015); in transplant recipients the rate ratio (cancer rate on nicotinamide divided by rate on placebo) was 1.0 (95% CI 0.8 to 1.3), with 207 versus 210 new skin cancers (Allen et al., 2023).

Evidence is indirect: trials used nicotinamide, not NAD+. In a 57-person crossover trial by Hui, nicotinamide alongside standard glaucoma treatment improved retinal nerve-cell function on electrical testing. A 2026 systematic review found visual field effects inconsistent (Giudiceandrea et al., 2026). Net reading: a short-term retinal signal, unproven against progression.

Magnitude: Retinal nerve-cell response amplitude improved 14.8% (95% CI 2.8 to 26.9) on nicotinamide versus 5.2% (95% CI −4.2 to 14.6) on placebo, not compared between groups (Hui et al., 2020).

Inflammation ⚠️ Conflicted

Evidence is indirect (precursors, mostly niacin and nicotinamide). Pooled precursor trials lowered C-reactive protein (CRP, a blood marker of inflammation). After four IV NAD+ infusions, high-sensitivity CRP did not change in a wellness chain’s own retrospective series (Reyna et al., 2026). Net reading: small precursor effect, unshown for NAD+.

Magnitude: CRP was 0.93 mg/L lower than control (95% CI −1.47 to −0.40) (Sohouli et al., 2024).

Blood lipids ⚠️ Conflicted

Evidence is indirect. Pooled precursor trials improved lipids, driven mainly by nicotinic acid (niacin), with no effect from NR or nicotinamide. After IV NAD+, HDL (“good”) cholesterol fell in a small uncontrolled series (Reyna et al., 2026). Net reading: lipid benefits belong to niacin, not NAD+.

Magnitude: LDL (“bad”) cholesterol was lower with precursors than control, SMD −0.38 (95% CI −0.50 to −0.27) (Zhong et al., 2022).

Substance-use cravings and withdrawal ⭕️ Not Central to Health & Longevity

Uncontrolled reports describe IV NAD+ easing withdrawal and cravings. In 50 treatment-resistant patients, NAD+ infusions combined with amino acids and B vitamins lowered craving, anxiety and depression scores, so NAD+’s own contribution is unclear. No controlled trial exists. This bears on addiction treatment, not healthy aging.

Magnitude: All 40 patients tested midway through the infusion course had negative urine drug screens (no control group) (Blum et al., 2024).

Melasma ⭕️ Not Central to Health & Longevity

In 36 Korean women, microneedling (tiny skin punctures) followed by topical NAD+ reduced melasma (patchy facial pigmentation) over 21 weeks. Evidence is indirect: skin delivery combined with microneedling, without a control group. This bears on skin appearance, not healthy aging.

Magnitude: The melasma severity score fell from 16.8 to 6.9, a 59% reduction (no control group) (Yi et al., 2026).

Speculative 🟨

Muscle NAD+ is lower in impaired older adults (Janssens et al., 2022), but whole-blood NAD+ did not vary with age (Trętowicz et al., 2026). Both are unvalidated biomarkers. Net reading: an age-related deficit is unproven.

Lifespan extension ⚠️ Conflicted

NR extended mouse lifespan in one study (Zhang et al., 2016) but not in the Interventions Testing Program (Harrison et al., 2021). No human lifespan data exist. Net reading: inconsistent animal evidence.

Mitochondrial function ⚠️ Conflicted

NMN improved energy metabolism in aging mice (Mills et al., 2016), but NR did not change muscle mitochondrial respiration in obese men (Dollerup et al., 2020). Both are unvalidated measures. Net reading: no human benefit.

Benefit-Modifying Factors

  • Genetic variation: No variant has been tested as a modifier of NAD+ response. Liver NNMT activity, which clears excess nicotinamide, varies widely, with about a quarter of people in a high-activity group (Rini et al., 1990), which may affect retention.
  • Baseline metabolic status: Precursor effects on lipids appeared mainly in people with cardiovascular disease or abnormal lipids, with little effect in healthy people (Zhong et al., 2022).
  • Baseline NAD+ levels: Whole-blood NAD+ does not track age or lifestyle, so a “low” reading cannot yet identify likely responders (Trętowicz et al., 2026).
  • Sex: Key trials enrolled one sex only, prediabetic women for NMN (Yoshino et al., 2021) and obese men for NR (Dollerup et al., 2018), so sex differences in benefit are unknown.
  • Pre-existing conditions: The only controlled benefit of NAD+ itself is in ischemic heart failure (Yu et al., 2026); fatigue signals come from chronic fatigue syndrome (Castro-Marrero et al., 2015); in early Parkinson’s disease the precursor NR worsened symptoms (Brakedal et al., 2026).
  • Age: NMN lowered systolic pressure only in adults aged 60 or older (Zhang et al., 2026), yet in adults over 60 NMN and NR did not improve muscle mass or function (Prokopidis et al., 2025).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: infusion reactions and other harms come from small retrospective series, adverse-event reports and indirect precursor trials, not from replicated controlled trials of NAD+.

Medium 🟥 🟥

No risk reaches Medium: the only comparative data on direct NAD+ harms are a small retrospective series and a tiny randomized pilot that conflict, and the remaining harm data are case reports or indirect precursor trials.

Low 🟥

Infusion reactions during intravenous NAD+ ⚠️ Conflicted

IV NAD+ often causes nausea, cramping, vomiting, chest pressure and a rapid heart rate, likely from a surge of extracellular NAD+. In a wellness chain’s retrospective series, all self-paced recipients had moderate to severe symptoms; a randomized slow 6-hour infusion caused none. Net reading: reactions appear rate-dependent.

Magnitude: Moderate to severe infusion symptoms occurred in 6 of 6 people given 500 mg IV NAD+ versus 0 of 8 given IV NR (5 of 8 had only minor tingling or cramping); NAD+ infusions took an average 97 versus 37 minutes (Reyna et al., 2026); no adverse events occurred in 8 people given 750 mg over 6 hours or in 3 given saline (Grant et al., 2019).

Contamination reactions from compounded injections

The US Food and Drug Administration (FDA, the drug regulator) received reports of severe chills, shaking, vomiting and fatigue after NAD+ injections, consistent with endotoxin (bacterial toxin) contamination from food-grade ingredients (FDA, 2024). Reviews also note procedural risks of IV therapy (Godic & Townsend, 2026). Evidence is case reports only.

Magnitude: Not quantified in available studies. Only spontaneous adverse-event reports exist, with no count of infusions given and no comparison group.

General side effects of oral forms ⚠️ Conflicted

Evidence is indirect (NADH and precursors, not NAD+). Reviews list muscle pain, headache, fatigue and sleep disturbance (Gindri et al., 2024), but a meta-analysis of placebo-controlled NMN trials found no excess adverse events (Yang et al., 2026). Net reading: oral forms appear no worse than placebo short-term.

Magnitude: Serious adverse events occurred in 8.3% with NR versus 14.1% with placebo over 52 weeks (Brakedal et al., 2026); pooled NMN trials showed no excess in overall, serious or withdrawal-causing adverse events.

Worsening of Parkinson’s disease ⚠️ Conflicted

Evidence is indirect (NR, a precursor). In the 410-patient Norwegian NOPARK trial, NR 1,000 mg/day for 52 weeks worsened overall and non-motor symptom scores versus placebo in early Parkinson’s disease; the mechanism is unknown. A 30-patient pilot had suggested improvement. Net reading: the larger, longer trial carries more weight.

Magnitude: MDS-UPDRS total 2.72 points worse than placebo (95% CI 0.47 to 4.98) and non-motor symptom score 4.22 points worse (95% CI 1.07 to 7.37) (Brakedal et al., 2026; Brakedal et al., 2022).

Higher blood glucose ⚠️ Conflicted

Evidence is indirect (precursors). Pooled precursor trials raised fasting glucose and HbA1c, mostly with nicotinic acid, whereas NMN trials showed no glucose change (Chen et al., 2024). Net reading: the risk appears tied to niacin-type precursors rather than NAD+.

Magnitude: Fasting glucose was 2.17 mg/dL higher (95% CI 0.68 to 3.66) and HbA1c 0.11 points higher (95% CI 0.06 to 0.16) than control (Sohouli et al., 2024).

High vitamin B3 load from stacked products ⚠️ Conflicted

Evidence is indirect (nicotinic acid, not NAD+). Some NAD boosters exceed the vitamin B3 upper limit (ConsumerLab), and 2 g/day extended-release niacin with laropiprant (a flushing blocker) raised serious adverse events in HPS2-THRIVE. Pooled precursor trials showed no liver-enzyme rise. Net reading: harm is tied to high-dose nicotinic acid.

Magnitude: Serious gastrointestinal, musculoskeletal and skin adverse events were 1.0, 0.7 and 0.3 percentage points more frequent than with placebo over a median 3.9 years (HPS2-THRIVE Collaborative Group, 2014); liver enzymes did not change in pooled precursor trials (Sohouli et al., 2024).

Speculative 🟨

Cancer growth and chemotherapy resistance

In pancreatic cancer cells and mice, NMN and nicotinamide helped tumors survive chemotherapy and grow (Nakazzi et al., 2026). Basis is cell and animal data only; no human cancer outcome data exist.

Amplified inflammation from senescent cells

In cell and mouse studies, higher NAD+ fueled the inflammatory secretions of senescent cells (Nacarelli et al., 2019). Basis is mechanistic only; human relevance is untested.

Depletion of methyl groups

Clearing excess nicotinamide through NNMT uses methyl groups (chemical tags for gene regulation), which could raise homocysteine (an amino acid linked to heart risk) at high doses. Basis is mechanistic only; untested in NAD+ trials.

Risk-Modifying Factors

  • Genetic variation: No pharmacogenetic data exist. Bimodal liver NNMT activity (Rini et al., 1990) may alter how much nicotinamide is methylated, theoretically changing methyl-group demand.
  • Baseline glucose: People with prediabetes or diabetes may be more affected by the glucose rise seen with niacin-type precursors (Sohouli et al., 2024).
  • Sex: Harm data are not reported by sex; infusion and precursor safety studies were small or single-sex, so sex differences in risk are unknown.
  • Parkinson’s disease: In early Parkinson’s disease, NR worsened symptom scores versus placebo (Brakedal et al., 2026).
  • Cancer: Active cancer, especially during chemotherapy, raises theoretical concern because precursors protected pancreatic tumors in mice (Nakazzi et al., 2026).
  • Heart conditions: Rapid infusions raise heart rate and cause chest pressure (Reyna et al., 2026), which may be less tolerable with heart disease (theoretical).
  • Age: Older adults more often have heart disease, diabetes or Parkinson’s disease and take more medications, increasing exposure to the risks above; no age-specific safety data exist.

Key Interactions & Contraindications

No human drug-interaction study of NAD+ has been published; the entries below are inferred from mechanism or animal data unless stated otherwise.

  • PARP inhibitors (olaparib, niraparib, talazoparib): Avoid (theoretical). PARP inhibitors (cancer drugs that block the NAD+-consuming DNA-repair enzymes) could be blunted by extra NAD+. Mitigation: no NAD+ products during treatment without the oncologist’s agreement.
  • Chemotherapy (gemcitabine, oxaliplatin, 5-fluorouracil): Avoid (theoretical). NMN and nicotinamide made pancreatic tumors in mice more resistant to these drugs (Nakazzi et al., 2026), risking reduced treatment effect. Mitigation: pausing NAD+ products during chemotherapy.
  • Blood pressure medications (amlodipine, lisinopril, losartan): Monitor (theoretical). NMN modestly lowered diastolic pressure (Zhang et al., 2026), so effects could add, with a small risk of dizziness. Mitigation: home blood pressure checks in the first weeks.
  • Glucose-lowering drugs (metformin, insulin, glipizide): Monitor (theoretical). Niacin-type precursors raised glucose and HbA1c (Sohouli et al., 2024), which could offset diabetes treatment. Mitigation: HbA1c recheck after 3 months.
  • Over-the-counter niacin (nicotinic acid) and nicotinamide: Caution. Stacking adds vitamin B3 load; ConsumerLab notes some NAD boosters already exceed the B3 upper limit (ConsumerLab), risking flushing and liver strain. Mitigation: totaling B3 across all products.
  • Other over-the-counter drugs (acetaminophen, ibuprofen, cetirizine, omeprazole): No interaction known or studied; monitor for unexpected effects.
  • Supplements NR, NMN and NADH: Monitor (theoretical). Combining with NAD+ adds to the same pathway and B3 load without evidence of extra benefit. Mitigation: one NAD+-raising product at a time.
  • CD38-inhibiting supplements (apigenin, quercetin) and resveratrol or pterostilbene: Monitor (theoretical). Often combined to slow NAD+ breakdown or activate sirtuins; effects may add, but no human data show added benefit or harm. Mitigation: introducing one at a time.
  • Methyl donors (trimethylglycine, methylfolate): Low concern (theoretical); potentially protective. Some products add them to offset methyl groups used to clear nicotinamide; untested. Mitigation: none needed.
  • Alcohol: Caution (theoretical). Alcohol metabolism converts NAD+ to NADH, so heavy drinking consumes NAD+ and may cancel supplementation. Mitigation: limited intake.
  • Other infusions (glutathione, vitamin cocktails) in the same session: Caution. FDA has warned against supplement-grade ingredients in injectables, raising contamination risk (FDA, 2024). Mitigation: confirmation of sterile, pharmaceutical-grade components.

Populations who should avoid NAD+:

  • People with active cancer or receiving chemotherapy or PARP inhibitors (theoretical; animal data) (Nakazzi et al., 2026)
  • People with early Parkinson’s disease, diagnosed within 2 years and Hoehn and Yahr stage below 3 (a disability staging scale), the group in which NR worsened symptoms (Brakedal et al., 2026)
  • Pregnant or breastfeeding women (no safety data)
  • Children and adolescents (no safety data for NAD+ itself)
  • For IV use: people with unstable heart rhythm, recent chest pain or uncontrolled heart failure (theoretical; infusions raise heart rate and cause chest pressure)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Slow infusion rate: Prevents nausea, cramping and chest pressure; a 750 mg infusion over 6 hours caused no reported adverse events (Grant et al., 2019), whereas faster self-paced infusions caused symptoms in all recipients (Reyna et al., 2026).
  • Sterile pharmaceutical-grade product: Prevents endotoxin reactions; FDA warns against food-grade NAD+ in injectables (FDA, 2024). Reputable clinics name their compounding pharmacy and share its certificate of analysis.
  • Licensed clinical setting: Reduces preparation and administration errors, one possible, not yet determined cause of a 2026 death after an infusion at a New York wellness clinic (Mazin, 2026); infusions are given with trained staff and emergency equipment.
  • Stopping at warning symptoms: Prevents escalation of infusion reactions; the infusion is slowed or stopped for chest pressure, palpitations or vomiting, and medical care is sought for chills or shaking afterward, the symptoms FDA linked to endotoxin (FDA, 2024).
  • Pausing during cancer treatment: Avoids possible tumor protection seen in mice (Nakazzi et al., 2026); NAD+ products are stopped for the full course of chemotherapy or PARP inhibitor treatment.
  • NR avoidance in Parkinson’s disease: Prevents the symptom worsening seen with 1,000 mg/day NR over a year (Brakedal et al., 2026).
  • Glucose checks with niacin-type products: Detects the glucose rise linked to precursors (Sohouli et al., 2024); fasting glucose and HbA1c at baseline and after 3 months.
  • Total vitamin B3 count: Prevents high vitamin B3 load from stacked products; B3 is totaled across all products and kept far below the 2 g/day niacin that raised serious adverse events (HPS2-THRIVE Collaborative Group, 2014).

Therapeutic Protocol

Timing, cycling, and titration steps below reflect common practice unless cited. Two approaches compete, direct NAD+ and oral precursors, and neither is established as the default.

  • IV NAD+ in wellness clinics: 250 mg over about 1 hour every 2 weeks (Itani et al., 2026); 500 mg daily on 4 consecutive days (Reyna et al., 2026); 750 mg over 6 hours (Grant et al., 2019).
  • Who popularized IV NAD+: Addiction clinics such as Louisiana’s Springfield Wellness Center, whose staff co-authored the infusion pilot (Grant et al., 2019), later adopted by longevity and wellness clinics.
  • IV NAD+ trial regimen: 10 mg/day for 7 days with standard care in ischemic heart failure (Yu et al., 2026), a far smaller dose than wellness protocols.
  • Oral NAD+: 2,000 mg/day for 5 days of a modified powder that is half NAD+ by weight, in a manufacturer-sponsored trial (Kornilov et al., 2026); standard oral NAD+ is largely broken down in the gut.
  • Nasal and patch NAD+: Nasal spray 30 mg/day (NCT07475546) and 400 mg iontophoresis (electrically driven skin) patch weekly for 4–6 hours (NCT04604704), both in AgelessRx trials; the company sells these products.
  • Precursor alternative: NR 500 mg twice daily (Brakedal et al., 2026) or NMN 250–2,000 mg/day (Chen et al., 2024); popularized by Charles Brenner for NR (Bieganowski & Brenner, 2004) and Shin-ichiro Imai for NMN (Mills et al., 2016).
  • Time of day: Morning or early-afternoon sessions and doses are common practice because NAD+ metabolism follows the body’s 24-hour clock and some report alertness; no trial has compared timing.
  • Half-life: No plasma half-life is established; with IV infusion, plasma NAD+ rose only after 2 hours and peaked at 6 hours (Grant et al., 2019), while oral NR keeps blood NAD+ raised with daily use (Wu et al., 2025).
  • Single or split dosing: IV NAD+ is given as single sessions; oral precursors are often split twice daily, as in trials of NR 1,000 mg twice daily (Dollerup et al., 2018).
  • Genetics: No genotype-guided dosing exists; individual NNMT activity varies widely (Rini et al., 1990), which could alter the dose needed.
  • Sex: No sex-specific dosing data exist; key trials enrolled only women or only men.
  • Age: Adults over 60 showed the clearest blood pressure response to NMN (Zhang et al., 2026); slower infusions are common practice for older people.
  • Baseline biomarkers: No validated NAD+ level guides dosing, because whole-blood NAD+ does not track age (Trętowicz et al., 2026); baseline glucose guides choice between precursor types.
  • Pre-existing conditions: Heart failure has a trial-tested IV regimen; Parkinson’s disease argues against NR; active cancer argues against all NAD+-raising products.

Discontinuation & Cycling

  • Lifelong or short-term: No trial of NAD+ itself, NR or NMN has run beyond 52 weeks (Brakedal et al., 2026); IV NAD+ is typically given in episodic series, and long-term continuous use is untested.
  • Withdrawal effects: None reported after stopping IV NAD+, oral NAD+ or precursors in published trials.
  • Tapering: Not needed; there is no known dependence or rebound, so products can be stopped at once.
  • Effects after stopping: Benefits appear to require continued use; nicotinamide’s skin-cancer protection disappeared within 6 months of stopping (Chen et al., 2015).
  • Cycling: No study shows cycling preserves benefit. NR lowered muscle NAMPT (the main NAD+ recycling enzyme) by 14% (Dollerup et al., 2020), a possible feedback effect sometimes used to justify breaks (theoretical).

Sourcing and Quality

  • Injectable NAD+: Sterile, pharmaceutical-grade material from a state-licensed compounding pharmacy or FDA-registered outsourcing facility matters most; FDA found compounders using food-grade NAD+ for IV products (FDA, 2024).
  • Oral NAD+ and NADH: Standard oral NAD+ is broken down in the gut; modified formulations claim better uptake, but the supporting trial was manufacturer-sponsored (Kornilov et al., 2026).
  • Precursor products: ConsumerLab found most tested NAD+, NADH, NR and NMN products contained their listed amounts without contamination, but NR content depends on the salt form used (chloride or hydrogen malate) (ConsumerLab).
  • Third-party testing: Independent verification (ConsumerLab, USP (United States Pharmacopeia) or NSF International seals) and a lot-specific certificate of analysis showing identity, purity and, for injectables, sterility and endotoxin results indicate quality.
  • Brands used in research: Niagen (NR) appears in many trials, MIB-626 (NMN) in Bhasin-group trials (Pencina et al., 2023) and LathMized NAD+ in its maker’s trial; research use does not confirm clinical benefit.

Practical Considerations

  • Time to effect: IV NAD+ raises plasma levels within hours; oral NR raises blood NAD+ within 5 weeks (Wu et al., 2025); the heart-failure benefit was measured at 1 month (Yu et al., 2026).
  • Common pitfalls: Assuming oral NAD+ is absorbed intact; equating higher blood NAD+ with better health; rushing infusions; using unlicensed clinics; stacking several vitamin B3 products.
  • Regulatory status: In the US, injectable NAD+ is made by compounders; FDA warned in October 2024 that some used food-grade NAD+ unsuitable for sterile products (FDA, 2024). Oral forms are marketed as supplements.
  • Cost and access: IV series are expensive, repeated and paid out of pocket. Because insurers and national health systems cover neither IV NAD+ nor oral precursors for wellness, no payer incentive shapes this evidence; most direct NAD+ studies are funded by clinics or manufacturers.

Interaction with Foundational Habits

  • Sleep: Direction: indirect and uncertain. NAD+ metabolism follows the body’s 24-hour clock, and late-day infusions are anecdotally linked to poorer sleep. NR did not improve sleep quality versus placebo in long COVID (Wu et al., 2025). Practical: infusions and doses are usually scheduled early in the day.
  • Nutrition: Direction: potentiating. Diet supplies NAD+ building blocks (tryptophan from protein; niacin from meat, fish, legumes and whole grains), and adequate vitamin B3 intake already provides the base material (ConsumerLab). Heavy alcohol use consumes NAD+. Practical: protein-adequate diet, limited alcohol.
  • Exercise: Direction: potentiating and overlapping. Training raises NAMPT about 1.46-fold (Sun et al., 2023), and trained older adults keep muscle NAD+ near young levels (Janssens et al., 2022). In Friedreich’s ataxia (an inherited nerve disease), NR plus exercise was not better than exercise alone for fitness (Lin et al., 2026).
  • Stress management: Direction: none shown. No human study has measured NAD+ effects on cortisol; NR did not change anxiety or depression scores versus placebo (Wu et al., 2025). Practical: infusion discomfort is itself stressful, so slower rates help.

Monitoring Protocol & Defining Success

Baseline testing before starting typically covers blood pressure and resting heart rate, fasting glucose and HbA1c, liver enzymes and kidney function, together with a two-week diary of energy, sleep and exercise recovery. These values provide the comparison points for later changes, since no NAD+ blood level defines success.

Ongoing monitoring typically follows this cadence: blood pressure and heart rate before, during and after every infusion; laboratory tests at 4 weeks, at 3 months, then every 6–12 months while use continues. Whole-blood NAD+ testing is optional and only confirms uptake. Success is defined by improvement in the symptoms that prompted use, without worsening glucose, liver or kidney results. In common practice, use is stopped when no change appears after 3 months.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure No established target; compare with own pre-infusion reading Safety check: infusion reactions and possible additive lowering Seated, after 5 minutes’ rest; measure before, during and after IV sessions
Resting heart rate 60–100 beats/min (standard reference range) Safety check: rapid infusions raise heart rate Pair with blood pressure; a rise during infusion signals the infusion rate is too fast
Fasting glucose 70–99 mg/dL (standard reference range) Safety check: niacin-type precursors can raise glucose 8–12 hour fast; morning draw; pair with HbA1c
HbA1c 4.0–5.6% (standard reference range) Safety check: detects sustained glucose rise HbA1c (3-month average blood sugar); no fasting needed; repeat after 3 months
ALT and AST ALT about 7–56 U/L, AST about 8–33 U/L (standard reference range) Safety check: liver strain from high vitamin B3 loads ALT and AST (alanine and aspartate aminotransferases, liver enzymes); no intense exercise 24 hours before; ranges vary by lab
Creatinine About 0.74–1.35 mg/dL in men and 0.59–1.04 mg/dL in women (standard reference range) Safety check: NAD+ breakdown products leave through the kidneys Usually reported with eGFR (estimated glomerular filtration rate, kidney filtering capacity); good hydration and no heavy meat meal before testing; ranges vary by lab
Whole-blood NAD+ No established target; track change from own baseline Expected to change: confirms uptake Dried-blood-spot or whole-blood tests; does not track age, so only meaningful as a before-after comparison

Qualitative markers:

  • Daytime energy and fatigue
  • Sleep quality
  • Exercise recovery and endurance
  • Mental clarity and focus
  • Mood
  • Infusion tolerance (nausea, cramping, chest pressure)

Emerging Research

  • Oral NAD+ absorption trial: NCT07692633, not yet recruiting, 80 healthy adults; primary endpoint whole-blood NAD+ change at day 56 versus placebo. A positive result would show oral NAD+ raises levels; a null result would support breakdown before absorption.
  • NR for blood pressure: NCT03821623, phase 2, active, not recruiting (completion 2027), 118 adults with elevated systolic pressure, 3 months NR versus placebo. A positive result would strengthen the blood pressure signal (for precursors); a null result would remove the main cardiovascular rationale.
  • High-dose NR and brain energy: NCT07649161, recruiting, 50 healthy adults taking NR 3,000 mg/day for 2 weeks; primary endpoint brain NAD+/NADH ratio. A positive result would show oral precursors reach the brain; a null result would weaken brain-health claims.
  • Combination longevity trial: NCT07475546, 30 participants, nasal NAD+ 30 mg/day with low-dose naltrexone, metformin and vitamin B12, with or without rapamycin; endpoints include VO2max (maximal aerobic capacity). Registered completion April 2026 has passed; listed as active, not recruiting, with no results posted.
  • NAD+ and NMN in immune thrombocytopenia (an autoimmune loss of blood platelets): NCT06776510, registered with IV “Coenzyme I for Injection” 100 mg/day plus NMN. Registered completion March 2026 has passed; still listed as recruiting. Published results cover oral NMN only: 5 of 25 patients met the platelet-response endpoint (Li et al., 2026).
  • Replicating the heart-failure benefit: The only controlled benefit of NAD+ itself comes from one center (Yu et al., 2026); an independent multicenter replication could raise its grade, while failure would leave no controlled support.
  • Placebo-controlled wellness infusions: No outcome trial has tested IV NAD+ for wellness (Gallagher & Emmanuel, 2026); such trials could confirm or remove the main rationale for clinic infusions.
  • Harm signals: Explaining why NR worsened Parkinson’s disease (Brakedal et al., 2026) and whether precursors feed human cancers (Nakazzi et al., 2026) could weaken the case for routine use.
  • Better biomarkers: Since whole-blood NAD+ does not change with age (Trętowicz et al., 2026), tissue-level measures are needed to identify who, if anyone, is truly deficient.

Conclusion

NAD+ is a molecule every cell uses to make energy and to power repair enzymes, and raising it has become a central idea in the longevity field. The case for taking NAD+ itself rests on a thin base. One controlled study found that short courses of infused NAD+ improved heart pumping in people with heart failure; beyond that, direct human evidence consists of small reports without comparison groups in addiction care, fatigue and skin treatment.

Most human data come from vitamin B3 relatives that the body turns into NAD+. These reliably raise blood levels, but studies of blood pressure, blood sugar, muscle, thinking and fatigue have shown small, inconsistent or absent effects, and in people with early Parkinson’s disease, symptoms worsened more than with placebo. Lifespan results in mice are mixed, and blood levels may not fall with age in healthy people.

On the risk side, infusions often cause nausea, cramping, chest pressure and a rapid heart rate when given quickly, and injectable products made from low-grade ingredients have been linked to contamination reactions. Possible effects on existing cancers and the effects of long-term use are unknown.

Much of the direct evidence on infusions, oral formulations and patches comes from clinics and companies that sell them, which limits its weight. For health-focused adults, the overall picture is of a biologically central molecule whose supplementation clearly changes blood levels but has so far shown little effect on how people feel, function or age.

Top - Benefits - Risks - Protocol